Switching to biological DMARDs versus cycling among JAK inhibitors in patients with rheumatoid arthritis and with inadequate response to JAK inhibitors: from FIRST registry
Objectives This study aimed to identify characteristics of patients with rheumatoid arthritis (RA) with an inadequate response to Janus kinase inhibitors (JAKi-IR) and evaluate the efficacy and safety of subsequent treatments.Methods This study included 434 patients with RA who started JAKi treatmen...
Saved in:
Main Authors: | Yoshiya Tanaka, Hiroaki Tanaka, Satoshi Kubo, Shingo Nakayamada, Yusuke Miyazaki, Yoshino Inoue, Shunsuke Fukuyo, Ippei Miyagawa, Kentaro Hanami, Yasuyuki Todoroki, Masanobu Ueno, Yurie Satoh-Kanda, Ayako Yamaguchi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2025-01-01
|
Series: | RMD Open |
Online Access: | https://rmdopen.bmj.com/content/11/1/e004987.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
JAK inhibitors: a new choice for diabetes mellitus?
by: Mengjun Zhou, et al.
Published: (2025-01-01) -
Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis
by: Martina Morelli, et al.
Published: (2018-01-01) -
Erratum: JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
Published: (2025-01-01) -
Monocyte STAT1 phosphorylation and treatment response of JAK inhibitors in chronic nonbacterial osteomyelitis
by: Motoshi Sonoda, et al.
Published: (2025-01-01) -
Proteins lead the way: JAK inhibitors as a new treatment option in toxic epidermal necrolysis
by: Benjamin Klein, et al.
Published: (2025-02-01)